Form 4: Vor Biopharma Inc. Executive Eyal C. Attar Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Eyal C. Attar, Chief Medical Officer of Vor Biopharma Inc., reports a transaction involving the withholding of shares to cover tax obligations related to restricted stock units.
Summary
- On May 6, 2024, Eyal C. Attar, the Chief Medical Officer of Vor Biopharma Inc., had 999 shares of common stock withheld to satisfy tax obligations.
- The shares were withheld at a price of $1.75 per share.
- Following the transaction, Attar directly owns 110,708 shares of Vor Biopharma Inc. common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a standard tax withholding transaction, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track changes in ownership and potential alignment of interests.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it involves a small number of shares withheld for tax purposes.
Key Dates
| Date | Description |
|---|---|
| 05/06/2024 | Date of the transaction where shares were withheld for tax obligations. |
| 05/07/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.